Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps

We have read the article published in the Journal by Suzuki and associates: “Distinct responsiveness to intravitreal ranibizumab therapy in polypoidal choroidal vasculopathy with single or multiple polyps.”1 In that paper, the prognosis of polypoidal choroidal vasculopathy (PCV) has been investigated by taking the response of the patients to intravitreal ranibizumab (IV R) monotherapy in the presence of a single or multiple polyps. The authors included 48 previously untreated eyes of 48 patients who received monthly IVR injections for 3 months, followed by pro re nata (PRN) injections.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research